# Sources — Audre Lorde

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 3, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Academy of American Poets. "Audre Lorde." Poets.org. Supports her birth as Audrey Geraldine Lorde on February 18, 1934, in New York City to parents who were immigrants from Grenada; her breast cancer and *The Cancer Journals* (Spinsters, Ink, 1980), which won the Gay Caucus Book of the Year award for 1981; *A Burst of Light* (Firebrand, 1988); her term as poet laureate of New York in 1991 and 1992; and her death of breast cancer in 1992. https://poets.org/poet/audre-lorde
2. Spelman College Archives. Audre Lorde Papers, finding aid, biographical note. Supports her birth on February 18, 1934, in New York; her writing on topics important to her "as a woman of color, as a lesbian, as a mother, and as a feminist"; her mastectomy and her refusal "to be victimized by the disease"; *The Cancer Journals* (1980); the diagnosis of liver cancer "six years after her mastectomy," when "she chose to pursue alternative treatments rather than to opt for more surgery"; and her death on November 17, 1992, on St. Croix. https://dev2.spelman.edu/_1_Docs-and-Files/archives/finding-aids/audre-lorde-collection.pdf
3. Smith TK. "How Audre Lorde's Experience of Breast Cancer Fortified Her Revolutionary Politics." *Literary Hub*, October 14, 2020 (the foreword to the Penguin Classics edition of *The Cancer Journals*). Supports the discovery "On Labor Day 1978, during a routine self-exam" of "a lump in her right breast," the diagnosis of malignancy and "the ensuing mastectomy," that she "chose never to hide the fact of her missing breast," that she refused to wear the "wad of lambswool pressed into a pale pink breast-shaped pad" (a quotation from the book), and that she was repeatedly scolded for posing a threat to cancer patient "morale." https://lithub.com/how-audre-lordes-experience-of-breast-cancer-fortified-her-revolutionary-politics
4. "Lorde, Audre Geraldine." *The Scribner Encyclopedia of American Lives*, via Encyclopedia.com. Supports her birth in New York City on February 18, 1934, her death on November 17, 1992, in Christiansted, St. Croix, her death of liver cancer, the spread of the original breast cancer, and the description "African American lesbian feminist and poet." https://www.encyclopedia.com/humanities/encyclopedias-almanacs-transcripts-and-maps/lorde-audre-geraldine
5. Brandman M. "Audre Lorde." National Women's History Museum, June 2021. Supports her birth on February 18, 1934, to immigrants from Grenada; her writing about her experience "as a Black lesbian woman"; *The Cancer Journals* (1980) and its 1981 award; *A Burst of Light* (1988) and its Before Columbus Foundation award; and the poet laureateship. It dates her breast cancer diagnosis to 1977, which the other sources do not support (see below). https://www.womenshistory.org/education-resources/biographies/audre-lorde
6. Popova M. "Audre Lorde on the Transformation of Silence into Language and Action." *The Marginalian*, May 20, 2016. Supports the benign tumor of 1977, after "a three-week period of uncertainty" (the author's summary), and quotes her 1977 talk to the Modern Language Association: "Your silence will not protect you." https://www.themarginalian.org/2016/05/20/audre-lorde-silence-visibility/
7. *Publishers Weekly*. Review of *A Burst of Light*, April 25, 1988. Supports the year of the liver spread: "In 1984, feminist poet Lorde learned that her breast cancer had metastasized to the liver." https://www2.publishersweekly.com/9780932379399
8. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025. Adjuvant treatment by stage and biology, endocrine therapy, and surveillance. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
2. Runowicz CD, et al. "American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline." *CA Cancer J Clin* 2016;66(1):43–73. Surveillance, lymphedema, bone health, vasomotor and sexual symptoms, distress, lifestyle, and the survivorship care plan. https://pubmed.ncbi.nlm.nih.gov/26641959/
3. Khatcheressian JL, et al. "Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update." *J Clin Oncol* 2013;31(7):961–965. History and examination schedule, yearly mammography, and no routine laboratory tests or imaging. https://pubmed.ncbi.nlm.nih.gov/23129741/
4. Burstein HJ, et al. "Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update." *J Oncol Pract* 2019. Tamoxifen for premenopausal women at lower risk, ovarian suppression for higher risk, and treatment duration. https://pubmed.ncbi.nlm.nih.gov/30523754/
5. Bedrosian I, et al. "Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline." *J Clin Oncol* 2024. Testing for patients diagnosed at 65 or younger. https://pubmed.ncbi.nlm.nih.gov/38175972/
6. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), breast cancer monograph. Cancer-related history and examination every 3 to 6 months for years 1 to 3; yearly mammography of the remaining breast after mastectomy; breast MRI only for high-risk criteria; no routine blood counts, chemistry, liver tests, tumor markers, or distant imaging in asymptomatic stage I to III survivors; on tamoxifen, a yearly gynecologic assessment with prompt evaluation of abnormal bleeding (no routine ultrasound or biopsy) and a clot-symptom inquiry at every visit; DXA only on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopause; lymphedema assessment and counseling at every visit; distress, depression, and anxiety screening at intervals; fatigue, cognitive, sexual, and vasomotor symptom review; lifestyle counseling; and second-cancer screening. https://patrickrutledge.github.io/topthirty/
7. Medicare Preventive Services reference (Aether Forge, 2026). The preventive visit template. https://patrickrutledge.github.io/preventative_services/
8. U.S. Preventive Services Task Force: A and B recommendations (depression, unhealthy alcohol use, intimate partner violence, hepatitis C, HIV), colorectal cancer screening (2021), cervical cancer screening (2018), statin use for primary prevention (2022), and prediabetes and type 2 diabetes screening (2021). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
9. Centers for Disease Control and Prevention. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations, 2023 (https://pubmed.ncbi.nlm.nih.gov/36893044/), and the Adult Immunization Schedule by Age (https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html).

## Editorial resolutions

- **Recent-death rule.** Lorde died in 1992. The case uses only what she published about her own illness, as her archive's finding aid, a published foreword to *The Cancer Journals*, reference biographies, and a review of *A Burst of Light* report it, with basic biographical facts. The full texts of *The Cancer Journals* and *A Burst of Light* could not be read (the library copies are access-restricted), so only facts and short quotations that appear in the fetched sources are used. No medical records, accounts by relatives or friends, or speculation about undisclosed conditions are used. The recent-death review rule applies.
- **What is documented and what is synthetic.** Documented (**D**): the benign breast tumor of 1977, the right breast lump found on Labor Day 1978, the diagnosis of breast cancer and the mastectomy that year, her refusal of a prosthesis, the liver spread in 1984 and her choice of alternative treatment rather than more surgery, and her death in 1992. Everything else in the modern episode is synthetic (**S**): the tumor size, grade, receptor status, recurrence score, and stage; the sentinel node biopsy; tamoxifen and its side effects; every score, vital sign, and laboratory value; the genetic counseling; and the preventive care. No source gives her tumor's biology or any treatment besides the mastectomy, and none is implied. The synthetic findings were kept low-risk and mild (minimal PHQ-9 and GAD-7 scores, mild hot flashes managed without medicine, normal screening results) so that nothing reads as a claim about her private health.
- **Diagnosis year.** The foreword to *The Cancer Journals* and the Spelman finding aid place the diagnosis and mastectomy in 1978, and the finding aid dates the liver diagnosis six years later, in agreement with the 1984 date in *Publishers Weekly*. The National Women's History Museum gives 1977 as the year of diagnosis; the 1977 event documented elsewhere is a tumor that proved benign. The case uses 1978 for the cancer and records the 1977 tumor as benign.
- **Her decisions.** Her refusal of a prosthesis is documented in her own words and is recorded as her considered choice. The synthetic patient chose a flat closure without reconstruction and does not wear an external prosthesis; every note records this without pressing it, and the consultant records it as respected. Her later choice of alternative treatment for the liver disease is recorded only as a claim, without comment, and plays no part in the episode. Reports that she was treated at a clinic in Switzerland with a mistletoe preparation appear in a library catalog description and secondhand excerpts that could not be fetched or verified, so they are not used.
- **Identity.** She is described as a poet, essayist, and novelist who wrote as a Black lesbian woman, a mother, and a feminist, in the words of the cited sources. The synthetic social history says she lives with her partner and her two teenage children; the partner is unnamed, gives no history, and is not a source of any statement. Her children are not named.
- **Quotations.** Two short quotations of Lorde are used, each as it appears in a fetched source: "wad of lambswool pressed into a pale pink breast-shaped pad" (quoted in the foreword) and "Your silence will not protect you" (quoted in *The Marginalian*). No other words are attributed to her. "Morale" is the foreword's quotation of the book.
- **Index age.** The modern episode presents her at 45, five and a half months after the mastectomy, in the survivorship period she wrote about in *The Cancer Journals*. The synthetic date of birth is February 18, 1981 (shift 47 years). The index visit on March 9, 2026 maps to March 9, 1979; the chronic-care visits on March 30, June 29, and September 28, 2026 and the preventive visit on October 19, 2026 map to the same days of 1979, all before the liver diagnosis of 1984. The synthetic diagnostic imaging, biopsy, and mastectomy are dated September 2025 (true frame September 1978), after Labor Day, to agree with the documented sequence; their exact days are synthetic, because no fetched source gives the date of the operation. Past medical history includes only the 1977 and 1978 events; family history is left empty because no fetched source covers it and the recent-death rule applies.
- **Preventive visit.** An adult preventive visit (age 45, so `preventive_adult`) was added on October 19, 2026 (true frame October 19, 1979). No sick visit was added, under the recent-death rule. Judgment calls: (1) the health risk assessment and the AUDIT-C of 1 (a glass of wine a few times a month) are synthetic and are not drawn from any source; (2) the cervical sample, the hepatitis B, hepatitis C, and HIV tests, and the fecal immunochemical test are ordered with no results recorded; (3) advance care planning records an unnamed health care agent and only general priorities (complete information and making her own decisions, which echo her documented stance), and deliberately records no treatment preference.
- **Focused visits.** The three chronic-care follow-ups (three weeks, sixteen weeks, and twenty-nine weeks after the first visit) are documented as focused visits on the CMID breast cancer monograph, and each lists every item the protocol calls for at that point, with its interval and status, including the items it does not call for (routine laboratory tests, tumor markers, distant imaging, DXA on tamoxifen alone, and echocardiography without trastuzumab). One protocol deviation is recorded: germline testing, indicated at diagnosis at 44, was not offered by her previous care team. It was found at intake and is recorded at the consultation visit with the corrective action, a genetic counseling request. The waiting list delayed counseling until early October; this is recorded at each visit, and the panel result is still pending at the end of the episode, so no germline result is recorded.
- **Consultation.** The medical oncology referral and the consultation by Beatriz Lozano, MD (a fictional consultant), on the day of the second visit, are **S**. The consultant answers the five referral questions with what the record shows happened afterwards: tamoxifen alone continued, with no ovarian suppression or chemotherapy; non-drug measures for hot flashes, with venlafaxine held in reserve and never needed; the yearly left mammogram in September and no routine blood tests or imaging; genetic counseling, which took place in October; and primary care visits every three months with oncology review twice a year.
- **Not used.** Her journal entries, her talks other than the 1977 talk, her later years on St. Croix, and accounts by friends and family were not used. Her height is not recorded in a fetched source; the 168 cm in the record is synthetic.
